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LETTER
Monica Healthcare: From the research laboratory to commercial
reality—A real-life case study
1 INTRODUCTION
It was 1986 when I started my academic role at the University of
Nottingham (UoN). Within one month, my wife—who had just
given birth to our second child—was diagnosed with an aggres-
sive cancer called adenocarcinoma. Tragically, she died after 12
months. It was horrendous but the university was fantastic and
told me to look after my family and put my research on hold
for a bit. When I returned to work, I was understandably more
interested in healthcare research and how electronics could
help.
A short time later, a highly respected colleague also died
of cancer—Professor Derek Kirk. He had been undertaking
research into foetal monitoring. I went to see him in hospital,
where he suggested carrying on his work with other colleagues
in my department. These two significant deaths in my life led
me to foetal monitoring as an area of my research.
Having now spent over 30 years as an electronic engineer at
the UoN, it is fair to say that the landscape for the academic
researcher has changed out of all recognition. The word “aca-
demic” is now a distant definition of a professional university
engineer, who is now driven by research league tables to create
impact in society and even employment for the benefit of all. It
is, therefore, no surprise that to do this means looking beyond
solving the micro-level challenges of the laboratory and mak-
ing connections, with external professionals who can help refine
your discoveries, and with industry leaders in order to commer-
cialise and scale up the product or process.
My journey has resulted in over 25 patents filed with col-
leagues in the Optics and Photonics Research Group at UoN
and jointly securing more than £20m funding and investment
from commercial and public sector partners. These are outputs
that you can never achieve on your own and the importance of
the team is vital.
A significant highlight has been the research, development
and technology transfer of a wearable wireless foetal and mater-
nal care medical device. This novel technology formed the basis
of a spin-out company, Monica Healthcare, to commercialise
this university research. The collaboration with Philips Health-
care and the subsequent sale of Monica to GE Healthcare gen-
erated significant revenue for the university and speeded up the
roll out of the technology now available to millions of women
and unborn babies around the world.
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This article sheds some light on the process by which an idea
in a university laboratory found its way into the arms of both
GEHC and Philips—two of the largest healthcare conglomer-
ates in the world.
2 THE EXISTING TECHNOLOGY AND
LIMITATIONS
So, it was in 1988 that myself and John Crowe (another aca-
demic engineer in our faculty) continued Prof Kirk’s pioneering
work on foetal monitoring. We set about pondering the chal-
lenge of improving the foetal monitors in hospital. In the 1960s
and 1970s, many technologies for monitoring the foetus and the
mother had been commercialised, including using a microphone
(phonocardiography) and abdominal foetal electrocardiogram
(fECG) by placing electrodes over the abdomen to pick up the
foetal heart.
By the 1980s, the technology had focussed on just one
solution using two transducers placed on a pregnant mother’s
abdomen—one for detecting a foetal heart beat (Doppler ultra-
sound) and the other for detecting mother’s contractions (an
abdominally placed strain gauge guard ring transducer called
a tocodynamometer - “TOCO”). By the 1990s, these two sig-
nals, one from the baby and one from the mother, had become
crucial for detecting the well-being of a foetus during labour.
For example, when a uterine contraction occurs, the foetal heart
rate (FHR) can drop as the blood supply to the foetus is dimin-
ished by the contracting uterus. The time it takes for the FHR to
recover is an indication of foetal health and its ability to survive
the rest of labour.
Both transducers (Doppler FHR and TOCO) are attached via
an elasticated belt around the mother’s abdomen and are called
a cardiotocograph (CTG). This arrangement, although state of
the art in 1990, presented several problems (and still does) such
as:
(i) The belts used to secure the transducers are uncomfortable
and need constant re-adjustment by the attending team as
the foetus moves lower in the uterus as labour progresses
or these belts simply slip on the abdomen. If the transduc-
ers are not re-positioned, errors in the monitored signal can
creep in, often without the care-team’s knowledge.
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(ii) With many CTGs, the mother is effectively tied to the bed
from the restricting belts, meaning that the obvious encour-
aging effect of gravity is not present during labour as effi-
cacy studies has suggested [1].
(iii) Ultrasound has problems penetrating fatty tissue, and
hence, high-body-mass-index (BMI) mothers have poor
FHR detection resulting in the potential to miss or mask
key FHR events [2].
(iv) When the foetal and maternal heart beats, the Doppler
ultrasound detects multiple mechanical movements of the
foetal heart valves and heart walls as well as the blood flow
both in the foetus and in the mother. This means that
the Doppler signal can have many components depend-
ing on the position of the transducer and the presentation
of the foetus. The problems here are that this can con-
fuse the autocorrelation algorithm that calculates the FHR.
Two beats can be detected, and hence, the highly prob-
lematic “doubling” in FHR can occur, i.e. a foetus whose
FHR is 120 bpm (normal) can be shown as 240 bpm or
worse still an FHR of 60 bpm (abnormal) can be portrayed
as 120 bpm (normal). Or, in the case of maternal blood
flow being erroneously detected, the heart rate can show
80 bpm, which is normal for the woman but very abnor-
mal for the foetus or in the case of an exhausted mother
can be above the FHR at say 160 bpm [3]. If the attending
team are unaware of these potential problems, they can take
no action when action is needed or take unnecessary action
when the foetus is in fact well. In both cases (although rare
∼1/1000), there is potential for serious consequences to
the mother or foetus.
(v) The contraction TOCO strain gauge is notoriously unreli-
able requiring careful positioning with the correct maternal
belt tightening allowing reliable contraction detection.
(vi) Finally (albeit recently), 50% or £2.4bn of NHS Resolu-
tion annual claims are from childbirth where the CTG is
often cited as problematic, indicating that improvements
were and are necessary [4].
Despite all these known problems, Doppler Ultrasound and
tocodynamometry had become the standard of care for labour-
ing women in the developed world. However, with these disad-
vantages, a possible opportunity existed for an improved prod-
uct and with 9M births/year (EU and USA) of which 80% were
monitored during antenatal and birth the market was there. Sig-
nificantly, the only alternative to detect the FHR was to use the
invasive method of a foetal scalp electrode that penetrated (by
∼1 mm) the foetal scalp. This was and remains the gold stan-
dard, but it can only be applied in the later stages of labour,
and as one would expect, most women and clinicians do not
like using it. There is also an invasive alternative to monitoring
contractions using a pressure sensing tipped catheter inserted
transvaginally into the uterus. Again, it can only be used in the
later stages of the labour and is even less liked by clinicians and
labouring women. The market was, therefore, ready for a safe
and acceptable alternative to Doppler ultrasound and tocody-
namometry.
FIGURE 1 Time trace of an fECG (F) and maternal ECG (M) detected
from the abdomen of a pregnant mother to be. Note the coincidence of F and
M at one moment and also the noise present between each ECG complex. This
is a particularly strong fECG signal
3 INITIAL RESEARCH
We knew that when abdominal fECG was tried in the 1960s
and 1970s, it worked well in some women, but not enough to
make it a practical monitor, but it was a promising research area.
So, we set off with the task of answering the question: Could
electrophysiological monitoring on the abdomen of a pregnant
mother detect both foetal heartbeats and contractions better
than Doppler ultrasound and tocodynanometer?
It was a wonderful challenge for an engineer to play with. A
foetus’s heartbeat electrocardiogram (ECG) on a good day on
the mother’s abdomen is around 10 µV (typically 3 µV), whereas
the mother’s heartbeat is between 1000 and 5000 µV on the
sternum, whilst on the abdomen, it can be 200 µV compared
to 3 µV for the foetal ECG (fECG) —a huge dynamic range
if you want to successfully monitor both. Add electrical muscle
and background electrical noise, and the isolation and detection
of the tiny fECG signal is highly problematic. Figure 1 shows
very clear signals detected on the abdomen illustrating fECG,
maternal ECG and the noise.
We started our research work in 1990 with a series of PhD
funding from the Engineering and Physical Sciences Research
Council (EPSRC), the Collaborative Awards in Science and
Engineering (CASE) scheme, the university, and the Malaysian
government (Malaysian Royal Family and its PM were ex gradu-
ates of Nottingham University) in an attempt to build a foetal
monitor that could detect these tiny signals. The Collabora-
tive Awards in Science and Engineering scheme is excellent
and involves an industrial partner adding a financial supple-
ment to an EPSRC PhD award to work in a future theme for
the company. We received financial support from our univer-
sity research fund (£7800—predecessor of the current EPSRC
Impact Accelerator Award) and the Royal Society (£5000) in
1992 and 1993, respectively. These were only small grants but
vital as they allowed us to build the electronics, and we were very
proud of our first FHR instrument in 1993. We presented this
to the Hospital Clinical Engineering Department only to find
out that our device failed BS5724 (a predecessor of BS60601),
the electrical safety standard for medical devices. Although this
was embarrassing, it was a fantastic lesson to our young med-
ical devices group forcing us to become fully knowledgeable
of the medical device safety standards. A skill-base that has
allowed us to design medical devices fit for purpose and taught
us that understanding the medical devices regulation places us in
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a strong commercial position. For those of you not aware of the
regulations surrounding medical devices, then, at first, the sub-
ject area is daunting especially as the EU Directive on medical
devices (MDD93/42) had not really come into play at the time
(1993), but it was evolving. Medical devices are graded based
upon their level of risk as Class I (lowest risk), IIa, IIb and III
(Invasive). Following the MEDDEV Guidance 2.4/1 rules for
Classification of Active Devices, our device is classified as Class
IIb. Anyone looking to commercialise their medical device must
understand the associated medical devices law before placing a
product on the market. Interestingly, the UK medical devices
community having originally aligned to the EU MDD93/42 and
its 2007 amendment were starting to understand the new EU
regulations of MDR745. However, as we know, Brexit is having
a big influence on regulatory matters, and at the time of writing,
the new law for the UK for medical devices will be under the
banner of “UKCA”.
We had built up a tremendous relationship with the Busi-
ness Director from Oxford Medical, Dr. Terrence Martin, who
was extremely knowledgeable on the existing Doppler technol-
ogy and fully aware of its limitations—but at the time it was
a case of Hobson’s choice. Our technology offered an alterna-
tive although in 1996 our FHR detection rate was only 40%.
To increase this, we applied (and received) an Action Medi-
cal Research (AMR) grant (£56,217) to build a portable FHR
device.
We had a champion in Professor David James, an Obstetri-
cian and Dean of the Medical School at Queen’s Medical Cen-
tre (Nottingham), where trials and modifications increased the
monitor’s sensitivity and reliability to ∼60%. The application
of the electrodes to a pregnant mother’s abdomen was imple-
mented by Karnie Bhogal a highly professional and knowledge-
able NHS midwife who stayed with us throughout the later years
of the project.
However, the required success rate (∼85%) needed for a
commercial product was still a distant objective. One of our final
foetal monitoring PhDs was a top French engineer (Jean Fran-
cois Pieri) visiting us on an Erasmus undergraduate program.
We offered him a PhD place in 1997, and a delightful working
relationship was developed during which we discovered a won-
derful book by Henry Ott on noise reduction techniques and
also the importance of an early morning coffee and croissants—
the French way!
4 FURTHER RESEARCH
By 2000, most of our efforts had been placed on the signal pro-
cessing, but if we could improve the quality of the raw abdomi-
nal signals, then extraction of the FHR would become easier. We
picked up a useful pragmatic philosophy from National Semi-
conductor’s analogue designers—“the problem is like an onion,
remove one layer only to find another”. We recognised that per-
severance and thoroughness was the key to achieving a success-
ful instrument.
From 2000 to 2004, we made considerable research steps.
I recall in 2001 the numerous researchers working on the sig-
nal processing of abdominal fECG data with moderate success.
I constructed a pros and cons graphic of each research cen-
tre. Key parameters surfaced: fidelity of the detection instru-
ment, no wireless link, a requirement for a leadless system, and
finally no real-time FHR extraction. These parameters, there-
fore, defined the high-level specification of our design require-
ments.
By late 2000, we had filed our first patent (EP1220640B1,
US7532923B1), completed one research programme grant from
AMR and now employed Jean Francois (after his PhD) on a sec-
ond AMR grant. The procedure at the time for filing patents
within a university was considerably easier than it is nowadays.
For example, we were required then to write a very short (one
paragraph) description of our invention, estimate a market size
and contact our equivalent of the technology transfer office
(TTO) in those days called “Office of Research Business Ser-
vices”. At this time, not many academics would file patents as
there was no real requirement in the university league table met-
rics, whereas, now, the TTO is much more embedded within our
Faculty of Engineering. Although there was budget available,
it was not very competitive. Furthermore, since we had many
projects funded under a CASE award, then often the company
would pay for the initial UK filing fee.
Nowadays, the university internal processes require staff to
submit an “IP Disclosure Form” containing: the problem, how
the invention addresses this problem, its key advantages, the
closest competitors, the prior art, a market analysis, which
companies may be interested in this patent, etc. If initially
approved by the University IP Commercialisation Office, then
the inventors are required to present their invention to the Fac-
ulty IP committee, where you have the chance to “sell” your
invention—somewhat like a “Dragons Den” but without the
business route. Budgets are strictly controlled and typically the
centre funds 66% and the faculty 33% but with the university
metrics requirements for generating income from IP then spin
outs and filing patents is often a necessity. Industrial partners
are, therefore, often sought early so as to release IP positions
when sensible. The ownership of the patent is the university;
however, an agreed royalty sharing scheme is in place for the
named inventors (and others) in the event of the patent being
commercialised or equity can be given if a spin-out is created
as in our case. Once approved, the inventor will interact with a
patent attorney using a hypothetical journal paper description
of the technology, and from this, construct a draft specifica-
tion sometimes with claims. The first stage is often to file in
the UK, which sets an international “priority date”. An inter-
national Patent Co-operation Treaty (PCT) application will be
filed at 12 months with claims, and your patent is published at
18 months. It is at this point that you can submit your journal
paper for publication as well—holding a journal paper back for
these 12–18 months often frustrates academics, and it is possi-
ble to publish just after the priority date but you should speak to
your patent attorney first or else you may lose your patent ! The
PCT process secures the option of filing applications in a wide
range of countries at a later date without the need to identify the
countries of interest at the point of filing. It simplifies interna-
tional patent filing and prosecution and defers costs. Typically,
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FIGURE 2 Three-channel (red) fECG system proposed in 2001 with a
common electrode (blue). As the foetus moves, the fECG can be seen on at
least one channel [5]
18 months after the PCT has been filed, the application pro-
ceeds to the national phase. The examination process resulting
in grant or rejection of the application occurs at the national
phase and is carried out independently by each national patent
office the application has been filed with. We mainly choose the
EU and USA territories, but on occasions, we did go further
afield (i.e. India, China, Japan etc.) if we felt the invention was of
high value. The sequential acronym I like to recall in this patent-
ing process is “FPG”—meaning Filed (priority date), Publish
(12–18 months later), Granted (can be anytime from 4 years to
10 years!)
A breakthrough came in the adoption of an abdominal three-
channel sensor (see Figure 2), along with a refined design of the
electronics. We published these findings in 2001 [5]—little did
we know that this paper would be cited on nearly 200 occasions
by 2020. Here, we also demonstrated (see Figure 3) the increase
in FHR detection with each version of the electronic instrumen-
tation having reduced noise.
The three-channel system presented us with another advan-
tage. If the foetus moves out of the range of one channel, it falls
into the range of another channel; this indicated movement—
invaluable for monitoring foetal well-being—and allowed us
to construct a second patent in 2002 by which time we were
achieving an FHR success rate of 70%. By now, we had over
500 recordings. We could see on each channel that the magni-
tude of the fECG signal varied as the foetus moved and often
disappeared beneath the noise. However, when this happens, it
would often appear on another channel; hence, combining this
gave us the higher FHR detection rate. We again realised that the
combination of several factors means that this is not a simple
“one problem solved will fix all scenario”—our onion analogy.
Interestingly, we were approached in 2002 by a Doppler
ultrasound CTG foetal monitoring company to validate their
Doppler ultrasound FHR device in the antenatal period (i.e.
when the mother’s waters were still intact) against our abdom-
inal three-channel low-noise fECG system. We collected raw
fECG signals in parallel with Doppler ultrasound on 40 mothers
at various gestations. We were, therefore, able to provide valida-
tion data for their CTG FHR algorithm, demonstrating that it
matched our beat-to-beat three-channel fECG data.
The significance of a Doppler CTG ultrasound company
approaching us cannot be underestimated. It was an acceptance
that our electrical detection method may well have real clini-
cal benefit, and hence, an opportunity was appearing in front
of our eyes. Our unique selling points (USPs) over belt-based
Doppler/TOCO were as follows:
(i) Simple electrodes adhering to mother’s abdomen, i.e. no
tight belts.
(ii) Electrical signals are not affected by high BMI unlike
Doppler ultrasound.
(iii) The mother is no longer tied to the bed providing more
maternal satisfaction and encouraging gravity to help with
the birth process.
(iv) Being a 100% passive electrical measurement opens itself
to the benefits of wireless wearable technologies.
(v) The clear signature differentiation between a maternal
ECG and an fECG dramatically reduces the possibility of
MHR/FHR confusion.
(vi) The uterus when contracting generates an electrical signal
called the electrohysterogram (EHG). We had confirmed
what other researchers had found that it was possible to
detect contractions electrically—potentially sidestepping
the unreliable and problematic tocodynamometer.
(vii) With Moore’s law on our side, we were able to neatly bun-
dle the solution into a single-wearable wireless flexible sub-
strate (patch) potentially being simple to apply.
In 2003, we further optimised the FHR algorithm by intro-
ducing fECG signature recognition both in terms of duration
and amplitude along with noise measurement allowing us to
accurately separate out the signals from the noise. By 2004, our
second patent [6] was finally filed. We spent the next 12 months
trying to license the technology. Our process was to write a one-
page technology summary document and circulate via our Uni-
versity TTO to the Tier 1 foetal monitoring companies at the
time. We had meetings with two of these companies and showed
them our results, our device, and evidence of real recordings on
over 500 pregnant mothers. However, we had no takers partly
because: our product still had to be packaged correctly; we
still only had a 70% FHR detection success rate; and we were
considered a “me too” product. We quickly changed tack and
secured small-scale funding (HEFCE HIRF—a regional inno-
vation fellowship scheme) of £15,900 to build a commercial
team and develop a business plan. This highly flexible fund-
ing allowed us to recruit Dr. Carl Barratt (another of our ex
PhD researchers), whose employer in Cambridge had folded—
























FIGURE 3 Increasing FHR detection rate as a function of gestation but with four improving versions of the electronic instrumentation showing the effect of
reducing inherent electrical noise
he would turn out to be a perfect CEO. We set about scoping
the plan for a possible spin-out. A JRC business plan success of
£25,000 and a Medici Fellowship for Carl lay the foundations
for this journey. This £25,000 business plan prize was highly
welcome. Myself and Carl built up the business plan with the
help of BioCity’s experienced staff. The Lachesis Fund (Uni-
versity Challenge Seed Fund managed at the time by Quester)
provided £15,000 for a due diligence confirmation that our two
patents had value—we received not only a confirmation, but
also the patent divisional law produced two more patents pro-
viding us with four patents.
5 THE TEAM, INVESTMENT
CONTRACTS AND EQUITY
By early 2004, we had presented several versions of our business
plan to the university and many investors. Our team was now
myself, Carl and Jean Francois (now back in Cannes, France)—
other academics dropped out as the commitment required to
drive this through was becoming significant. Looking inwards
at ourselves, we recognised that our team was still lacking an
apparent commercial edge, i.e. one “academic” engineer and
two recent post-doctoral engineers, albeit that all three of us had
worked in industry. In late 2004, I contacted Dr. Martin (Terry)
and invited him to join our team—fortunately for us, Terry had
left Oxford Medical and now ran his own sales and marketing
consultancy company. Terry had wide connections with leading
obstetricians around the world—an attribute that would secure
a rapid key opinion leader entry at many international hospitals
and high-level entry to the major foetal monitoring companies.
We offered sweat equity to Terry, but our potential investors said
that we could not give equity away without a cash injection. So, I
went back to Terry and said we cannot do this, but Terry said no
problem. He agreed with the investors to work for the proposed
spin-out 1 day/week for an agreed fee negotiating payment for
shares over the first 12 months.
Contracts arrived from our investors for £500k
[https://www.mobihealthnews.com/1690/monica-healthcare-
neonatal-care-startup-gets-16m]—and we had 10 days to digest
a 3-in thick document. Good news came through that my
application for a €150k Marie Curie EU grant to generate an
abdominal fECG trigger for magnetic resonance imaging was
successful. This required exactly the new technology that we
were proposing to build at our spin-out and provided the EU
mobility for one of its top engineers Dr. Jean Francois Pieri, to
work in the UK with us.
So, we now had a quality team (see Figure 4), with £500k
investment, a €150k EU grant, significant personal investment,
four patents, a university pipeline agreement, over 500 record-
ings, FHR success rate increasing with each version of the
device with highly supportive investors, and university. We were
now ready to start an exciting but unknown journey!
6 COMMERCIALISATION PHASE
On the 28th April 2005, we incorporated Monica Health-
care Ltd. Our management team and executive directors
consisted Carl as CEO, myself as CRO, Jean Francois as
CTO and Terry as CMO. Within one month, on the 24th
May 2005, we signed the investment agreement with our
investors for £500,000. Our location was BioCity, the ex
BASF/Boots site in the centre of Nottingham home to
many other incubator companies. Our offices were next
to the regional Medilink group, who were tremendously
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FIGURE 4 The Monica founders, Management team and Executive
Directors at incorporation (2005), from left to right: Barrie R. Hayes-Gill
(CRO), Jean Francois Pieri (CTO), Terry Martin (CMO) and Carl Barratt (CEO)
supportive with small grants, healthcare network access and
publicity.
We had a two-year, milestone-driven, business plan to achieve
CE mark for our first product AN24, an antenatal device con-
densing all of our university research and development into a
mobile-phone-size device with a Bluetooth wireless link and a
high-density internal 2-GB SD card. Data could be collected
and processed initially off-line to generate FHR—such process-
ing was quickly moved to real time within the AN24 and the
internal BT module allowed wireless transmission to a nearby
display.
Our first regulatory trial in 2006 was to prove that our device
(the AN24) could be used for overnight long-term monitor-
ing during the antenatal period, i.e. before labour and delivery
(L&D). This time though, the trial was not on our home terri-
tory but in a foreign country in Europe. We were in Utrecht,
Holland, superbly set up by Terry, engaging with the world’s
leading obstetrician in Professor Gerry Visser and his highly
professional team. We now had to manage a trial remotely for
the first time—flights to Utrecht were abundant, and we all vis-
ited time after time to ensure that our new device was man-
aged correctly. The most noticeable difference was the modus
operandi of the clinical engineering electrical safety department
at that time. Prof. Visser had informed them in advance that we
were due to arrive and they were to undertake incoming inspec-
tion of our AN24 device. This was not as simple as we expected,
but it was amazingly quick and one that we must recognise as
a stumbling block for evidence-based UK MedTech research.
The Utrecht clinical engineering department tested for auxiliary
and leakage currents, etc., adhering to BS60601 standard and
quizzed us on its performance. The notable difference from the
UK was the speed of validation—within 8 h, our device was
approved. But this was by no means a short-circuit approach
to approval—it was simply efficient and accurate with minimal
competent authority administration. Approval was given for our
device, and we were ready to start the trial under the approved
local hospital ethics for a non-CE approved device.
Over 120 mothers were monitored with our device over a
range of gestations. A further 20 women were monitored for 1 h
during labour and the FHR compared with the gold-standard
foetal scalp electrode. We had acceptable success rates of over
80% through all gestations overnight with BMI having no detri-
mental effect. As a blind test, we also manually and painstakingly
located the fECGs from the raw AN24 data by eye for ∼ 10 min
per mother. This acted as an independent test of the accuracy
of our extraction algorithm—locating for each subject ∼1200
fECG complexes. An acceptable correlation of 0.85 was found
compared to foetal scalp electrode.
As a team, we mastered the Medical Devices Directive 93/42
and its 2007 amendment—that early engagement and lessons
learned from our hospital clinical engineering department back
in 1993 held us in good stead. A series of international stan-
dards were studied, and standard operating procedures (SOPs)
were developed to satisfy the ISO13485 medical devices qual-
ity standard. At one stage, whilst in Dusseldorf airport, on the
way back from Medica, we were writing SOPs ready for our
CE submission neatly handed out to each of us by Carl. In the
summer of 2007, we submitted our full Technical File to our
Notified Body for audit. With some minor non-conformities
that we corrected, we received our CE mark for the AN24—a
portable FHR device for long-term (24-h) Holter monitoring of
FHR. The device also provided maternal heart rate (MHR) and
contained an accelerometer for movement context information.
This in-depth knowledge of the EU medical devices regulatory
process proved to be an asset for the company allowing us to
design future products with the European Directive in mind.
We achieved all of this in 30 months with two full-time (Carl
and Jean Francois) and two part-time (myself and Terry) staff.
We pressed on with our overnight monitoring application and
signed up over 20 distributors throughout Europe with mod-
est AN24 initial orders and minimum order quantities. Unfor-
tunately, the commercial success of an overnight instrument
was not as strong as envisaged. Fortunately, this was only one
of three primary markets presented in our original business
plan (April 2005): overnight monitoring, home-care, and L&D.
Hence, we still had market opportunities in the home-care and
L&D markets.
Significantly, one of the main messages that Terry was
bringing back around 2009 from the market was the require-
ment for an improved L&D monitor—here, the annual market
was > £250 M. Our European distributors, therefore, required
contractions to give our product a chance in the market. At that
point, we realised that we must accelerate the detection of the
EHG (Electrohysterogram) with the AN24. The EHG is the
electrical signal generated when a mother’s uterus contracts dur-
ing labour—hence contraction detection. Fortunately, we had
trialled on earlier research work at the university the detection
of the EHG using the same fECG electrodes, and it appeared
to work effectively albeit only on a few subjects.
To address this, we undertook extended trials again in Utrecht
and a new site at Witten (Germany) on the simultaneous detec-
tion of the TOCO and EHG signals during labour. In Witten,
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we had built another wonderful relationship with a young obste-
trician with tremendous energy and drive. Results poured out
from Witten and a series of publications followed not just at
Witten [7] but also in Utrecht [8]. We had excellent correlation
between TOCO and our EHG. What was more we could see
that the TOCO was highly unreliable often requiring readjust-
ment back to the Uterine Fundus (top of mum’s bump) as the
belt was either loose or slipped down the abdomen. In 2010,
we were now in a position to add detection of contractions to
our CE mark. Hence, we had not only an overnight monitoring
device but also a true CTG monitor for L&D—a market mainly
dominated by GEHC and Philips. We had captured all of the
university IP into a CE-regulatory-approved product, but our
biggest challenge was how best to package this product—we
would not arrive at this answer until 2013.
We were relying on the patience of our investors who
were extremely supportive partly because we met all of the
timelines we were set and partly because they believed in
our team. By 2010, we had received over £2.75M in invest-
ment (https://www.ukbaa.org.uk/catapult-venture-managers-
support-monica-in-developing-new-generation-products/)
and over £300k in grants.
Terry was still making connections around Europe and more
eminent obstetricians followed and used the AN24. Various
research projects were carried out with the device, and by 2012,
we had seen over 50 journal papers published from numerous
research hospitals around Europe. This provided a slow public-
ity for our device around the obstetric community backing up
an early clinicians’ advice to get the work published in obstetric
journals and gradually the message will get out. He was right!
The ultimate market we really wanted to address though was
the USA where obesity was a real problem in L&D. So, again,
Terry visited USA and met up with in particular Prof. Wayne
Cohen then working as an Obstetrician and Gynaecologist as
Chief of Obstetrics based at Sinai Hospital, New York. Prof.
Cohen agreed to manage a trial in the USA to place Doppler
ultrasound and abdominal fECG head to head against inva-
sive foetal scalp and intrauterine pressure catheters—these inva-
sive devices were part of normal care pathway in the USA for
difficult labours. We monitored 74 women through L&D at
three USA hospitals: Queens New York; Columbia New York;
and Temple University Hospital, Philadelphia. The results were
excellent and are summarised in Table 1 and published between
2011 and 2014 [2,9,10]. Here, we achieved the FHR success rate
of 85% (versus 72% for Doppler) and the root-mean-square
error (RMSE) accuracy of 5 bpm (12 bpm Doppler). For con-
tractions, we achieved the success rate of 97% (67% TOCO)
and the sensitivity of 89% (55% TOCO). The most significant
result was MHR, and FHR confusion for Doppler was 10%,
whilst for our device, it was 0.4%.
Back in the UK, a significant product development that
removed the reluctance for hospitals to purchase our product
was the introduction of the IF24 in 2011. The IF24 was an
interface device that received data from our Bluetooth trans-
mitter and was directly hardwired to the installed base CTG
machines. The IF24 input data is from the Bluetooth wireless
link and replaces the wired Doppler and TOCO connections.
TABLE 1 USA FDA trial results (2011) comparing the Monica AN24
versus the traditional Doppler/TOCO CTG [2,9,10]
FHR Monica CTG
Reliability (%) 85 72
Accuracy (RMSE) (bpm) 5 12
Contractions
Reliability (%) 97 67
Sensitivity (%) 89 55
Maternal HR
Confusion rate (%) 0.4 10
Foetal HR (BMI > 40)
Reliability (%) 86 66
The IF24 converted our FHR and EHG contractions data into
foetal scalp ECG and TOCO signal inputs, respectively, thereby
enabling usage of many features of the hospital’s CTG machines
such as alarms, printer, network facilities etc. The IF24 was a
significant step in our USP offering.
A more general key to the results presented in Table 1 was
“filling the rectangle”—a term we coined when plotting the
FHR success rate in rank order—see Figure 5. This plot, orig-
inally devised by Terry, shows the FHR success rate in the y-
axis and the x-axis represents the rank order patient number,
i.e. the highest patient FHR success rate is placed on the left,
whilst the lowest success rate is placed at the far right. If all
patients reached 100%, then we would have “filled the rectan-
gle”. The aim was to find out why each subject did not reach at
least 90%—a fact pressed on us by our highly focussed Chair-
man. It was never down to one feature, and often, it was a tem-
poral issue, i.e. the foetus would move and the signal would get
smaller—hence, three channels were essential. But so was lower
noise although not for every subject and not for every minute.
We had a list of about 10 parameters that needed addressing, and
we realised that this was our onion analogy again. It is certainly
a fine line between engineering common sense and an obsessive
compulsive disorder, which often revealed a surprising result
that one can patent.
In 2011, US Food and Drug Administration (FDA) approval
followed for FHR and contractions (EHG)—FDA approvals
are given K numbers and ours was “K101801”. Having once
built up the confidence of the FDA in our medical device design
abilities, we then included the interface IF24 (K112163) and
then added in MHR & activity (K112390). By 2012, we had a
fully cleared L&D CTG device to compete with the traditional
Doppler CTG devices that had been in existence for the past 35
years.
Although the AN24 had significant IP using the research gen-
erated at the university, our turnover was only £495,000 (see
Companies House, 2014), but it was still missing how best to
package our IP so as to offer a no choice alternative to hospi-
tals. This came with the development of our product the Novii.
This device used all of the same electronics, software and IP























HR Detection % (Success Rate) vs Patient Cohort % in Rank Order
FIGURE 5 “Filling the rectangle”—graphic illustrates in the y-axis the percentage success rate for each patient of a new medical device plotted against the
patient in rank order (x-axis). The aim of course is for 100% success in 100% of subjects; however, many medical devices achieve 90% success in 90% subjects. By
improving, the product results in a gradual movement of the trace towards a rectangle
FIGURE 6 The Monica AN24 (left) with real-time FHR extraction uses discrete electrodes. The Novii on the right shows the improved package, which
incorporated all of the IP from the AN24 into the small pod (white module) but with electrodes now delivered on a single PET substrate offering a truly wearable
foetal monitor
module. This module was magnetically coupled to a PET flexi-
ble substrate (patch) that contained all of the original five elec-
trodes of the AN24 on a monolithic PET substrate—again with
driven shielding. The Novii was much simpler to administer on
the mother by an easy peel and stick footprint. Figure 6 shows
the comparison between the AN24 and the Novii—a single sub-
strate, fixed electrode locations, no wires but containing all of
the upside university IP of the AN24, namely, low noise, three
channels, wireless, real-time processing and mobility.
We proved the equivalence between the AN24 and the Novii
substrate in an FDA USA trial. Prof. Wayne Cohen had now
moved to Arizona and he undertook this trial. Wayne was a
tremendous advocate of our technology, and he undertook his
task with wonderful professionalism. In 2014, we received FDA
510k clearance for the Novii (K140862). Product pricing was
set based upon our market appraisal, and both the AN24 and
the Novii were set competitively below current CTG Doppler
machines. But of course, we knew that if we increased our
installed base of Novii systems, then we would sell more single-
use patches, which is where our real business model lay.
At one of our many exhibitions/trade shows, GEHC
noticed our stand and eventually became our distributor in
2016. Sales and turnover grew, and we had considerable USA
penetration. Philips was also our European partner via a co-
development deal (https://hitconsultant.net/2016/01/13/
philips-monica-healthcare-collaborate-on-fetal-monitoring-
solution/#.X70ycGj7RPY). Further trials in the USA fol-
lowed (in Phoenix) that built up GEHCs confidence in our
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product, and by 2016, we now had a total of 12 patents (for
example [6, 12]).
On the 10th March 2017, GEHC acquired Monica for an
undisclosed sum with investors reaping 3.5× to 5.5× return on
investment [11, 13, 14].
7 LESSONS LEARNED
It has been a very long but extremely enjoyable journey. With
our 12 patents, a spin-out, securing venture funding, decipher-
ing the EU’s Medical Devices Directive and navigating entry
into the USA via the FDA’s 510k regulatory process was a con-
siderable achievement. Dr. Susan Huxtable, as Director of Tech-
nology Transfer, and all of the Research and Innovation team
(including Dr. Bruce Venning and Dr. George Rice) at the uni-
versity have been highly supportive and with us every step of
the way as well as highly supportive investors.
Funding to keep the company going through many lows
came from: the Stirling efforts of Carl to expertly pitch for eight
investment rounds; author experience in managing IP portfo-
lio and applying for non-diluting grants, including GRD, SBRI,
Medilink, Innovate, NTECH, Medici Fellowship awards (Carl
and myself) and KTI awards; and the engineering excellence
of Jean Francois in responding to Terry’s astute market surveil-
lance, trial management and distributor management that gen-
erated sales to keep the company ticking over and the investors
engaged eventually leading to the development of the Novii
product.
The sale of AN24s as research devices providing raw abdom-
inal foetal electrophysiological recorders allowed research cen-
tres to publicise via over 150 journal papers (by 2021) on the
usage and functionality of the Monica technology (see [15–17]).
It was interesting to note that, however, great the IP is, then it
is toothless if it is not packaged correctly, and developing both
the interface and a wearable patch neatly enabled this market
penetration.
The success of the Monica products and the recent awards of
the IET Healthcare Innovation and the RAE Colin Campbell
Mitchell awards has been tremendously satisfying to the whole
team. But it is just this, a true team effort, and without all par-
ties pulling together and recognising the importance of the aca-
demic founder and the university, then we would certainly not
have arrived at this success.
I would like to think that, 30 years on, we have also helped
foster a culture where PhD researchers and professional engi-
neering colleagues within our universities share a passion for the
translation of technological discoveries into commercial appli-
cations for the benefit of society.
Finally, I sincerely hope that the two tragic early deaths in
my life will be looking down on us with pride at what a group
of university academics with a professional team can achieve in
today’s university technology transfer world.
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Timeline
1990: Prof. Hayes-Gill and Prof. Crowe begin investi-
gating novel ways of electronically detecting foetal
heartbeats
1996: FHR detection around 40%
Action Medical grant
1997: FHR detection reaches 60%
2000: First patent
2001: 500 FHR subjects now recorded—completed sec-
ond Action Medical grant.
FHR detection rate now 70%
Industrial research grant(s)
2004: Second patent Filed
Herobic Innovation Research Fund of £15,900 to
commercialise technology
Winners of the JRC Biosciences Business Plan
Competition
2005: Secured venture capital, EU and private funding
Launch of spin-out Monica Healthcare.
Now four patents in portfolio
2007: EU CE mark awarded
First commercial product launched (AN24)
2009–10: Trials in New York hospitals
FHR detection 85%
2011: FDA clearance opens up lucrative US market
Interface IF24 launched connecting to installed base
CTGs.
2013: Fully wearable product launched (Novii)
2016: After six investment rounds GE Healthcare
becomes Monica’s exclusive US distribution partner.
Sales soar underpinned by two further investment
rounds
2017: 12 patents in portfolio
Sale of Monica Healthcare to GE Healthcare on
10th March 2017.
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